NEW YORK – Fujirebio and pharma firm AriBio said Wednesday that they have formed a strategic partnership to develop biomarkers for Alzheimer's disease and other neurodegenerative conditions.
Under the agreement, Fujirebio will gain access to clinical samples and data collected through AriBio's ongoing Phase III study for its lead anti-Alzheimer's compound AR1001. The study launched in the US in December 2022 and is scheduled to expand to other countries in 2023.
"AriBio is committed to advancing not just the treatment options for patients with Alzheimer’s disease and their families, but also the development of better diagnostics and improved characterization of this devastating disease. This initial partnership with Fujirebio is the first of several we plan to launch in the next few years as we expand our clinical programs into other areas of neurodegeneration," James Rock, president of AriBio's US office, said in a statement.
"Fujirebio continues to lead the industry in the development of high-quality, functional tests to improve clinicians' ability to detect and diagnose a variety of neurodegenerative conditions," Monte Wiltse, president and CEO of Fujirebio Diagnostics, said in a statement. "We continue to partner with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools."
Last year Fujirebio received FDA de novo classification for its Lumipulse G β-Amyloid Ratio (1-42/1-40) test, making it the first in vitro diagnostic available in the US for detecting the amyloid plaques associated with Alzheimer's disease.
Financial and other terms of the deal were not disclosed.